A study of retinal microvascular changes in Diabetic Macular Edema using the swept - source optical coherence tomography angiography (OCTA) after being treated with Anti-Vascular endothelial growth factors (Anti-VEGF)

Phase 3

Recruiting

• Conditions: DMEMicroaneurysm changesEnlarged FAZ ZoneCapillary non perfusion zone; Central- Enlarged Foveal avascular zone; involved DME; OCTA; Microaneurysm change

• Registration Number: TCTR20161010005
• Lead Sponsor: Ratchadapiseksompot Endowment Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-10
• Study Completion: 2017-10-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

- Patients diagnosed with Diabetic Macular Edema (DME).
- Age > 18 years of age who have signed an inform consent.
- Candidates to be treated with Intravitreous Anti-VEGF ( Aflibercept , Bevacizumab and Ranibizumab )
- No history of Anti-VEGF treatment within 3 months.
- No history of retina surgery.

Exclusion Criteria

- Presence of severe media opacities.
- Patients who have other disease: monoculus, eye injuries , glaucoma, uveitis, retinal vein occlusion, retinal arterial occlusion, hereditary and degenerative macular disease, retinal and choroidal detachment.
- Any previous treatment for DME e.g. Focal / Grid LASER , IVT steroid injection/implant with in 6 months.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MIcroaneurysm in ETDRS Grid 1 year Image J Software

Secondary Outcome Measures

Name	Time	Method
FAZ 1 year Image J ,Capillary non perfusion area 1 year Image J